Tidepath

Topics

Compounded semaglutide and tirzepatide

Also called compounded semaglutide, compounded tirzepatide, semaglutide sodium, semaglutide acetate

Pharmacy-made versions of semaglutide and tirzepatide: the FDA doesn't review them before they're sold, and the shortages that let pharmacies copy the brands ended in 2024 and 202513.

Status
Compounded versions are not FDA-approved, and as of April 2026 the FDA says neither semaglutide nor tirzepatide is on its drug shortage list13.
How it's taken
By injection

What it is

Compounding is when a pharmacist or doctor mixes or changes a drug's ingredients to make a medicine for one patient's needs1. Compounded drugs are not FDA-approved, which means the FDA doesn't review their safety, effectiveness or quality before they're sold1. They aren't generics either: a generic is FDA-approved as a match for the brand, and a compounded drug isn't2. Federal law covers compounding in state-licensed pharmacies and by doctors, and in outsourcing facilities2. State-licensed pharmacies, working under a section of the law called 503A, are mainly overseen by state pharmacy boards2. Outsourcing facilities, working under section 503B, register with the FDA, are inspected by it, and must meet manufacturing quality standards2.

What makes it distinct

Whether compounders may copy semaglutide and tirzepatide has depended on the FDA's drug shortage list3. Both drugs were in shortage from 20223. The FDA declared the tirzepatide shortage over in October 2024, re-evaluated that decision during a lawsuit, and reached the same conclusion in December 2024; it declared the semaglutide shortage over in February 20253. It then held off on enforcement for a set time (what it calls enforcement discretion), which ended for tirzepatide in March 2025, and for semaglutide in April 2025 for state-licensed pharmacies and May 2025 for outsourcing facilities3. As of April 2026, the FDA says a state-licensed pharmacy may not regularly make what are essentially copies of an available approved drug: the same active ingredient, at the same or a similar strength, given the same way, unless a prescriber documents a significant difference for that patient3. It says a product that adds another ingredient, such as vitamin B12, may still count as a copy3. Outsourcing facilities may make drugs from bulk ingredients (the raw drug substance) only if the ingredient is on a list of ingredients with a clinical need or the drug is in shortage, and the FDA says neither applies to semaglutide or tirzepatide3.

What the evidence shows

Compounded versions don't go through the FDA's review for safety, effectiveness and quality before they're sold5. In July 2024, the FDA warned about dosing errors with compounded semaglutide injections, some followed by hospital stays4. Most of the reports described people drawing up more than their prescribed dose from a multi-dose vial, and many of the patients had no experience giving themselves injections4. Others described prescribers miscalculating doses when converting between milligrams, milliliters and 'units'4. The FDA noted that compounders sell semaglutide at different concentrations (how much drug is in each milliliter) and sometimes give doses in 'units', while the approved injections are dosed in milligrams4. Reported problems included nausea, vomiting, stomach pain, fainting, dehydration, inflammation of the pancreas (pancreatitis) and gallstones4. The FDA has also received reports of bad reactions that may be related to compounded semaglutide or tirzepatide prescribed beyond what the approved label says: bigger doses, more frequent doses, or faster increases (titration)5. As of May 31, 2026, it had received 990 reports of adverse events (bad reactions) associated with compounded semaglutide and more than 730 associated with compounded tirzepatide5. It says these are likely undercounted, because state-licensed pharmacies that aren't outsourcing facilities don't have to report them, and that a report doesn't always show whether the drug caused the problem5. It also says many of the reported events look like those reported with the approved versions5. The FDA says some compounded semaglutide may be made from salt forms, versions of the molecule paired with sodium or acetate, which are different active ingredients from the one in the approved drugs45. It says it doesn't have information on whether these salts have the same chemical and drug properties, and knows of no lawful basis for compounding with them5.

Open questions

  • Whether the FDA will finalize its May 2026 proposal not to add semaglutide, tirzepatide or liraglutide to the list of bulk ingredients outsourcing facilities may use. The comment period closed on July 30, 2026, and our sources don't show a final decision78.
  • What the FDA's February 2026 plan to restrict GLP-1 ingredients meant for mass-marketed compounded drugs will look like in practice. The FDA announced the intent; our sources don't show the final steps6.
  • Whether the salt forms behave like the approved ingredient. The FDA says it doesn't have that information5.
  • What's in a given compounded product. Concentrations can vary between compounders, and the FDA doesn't check quality before sale14.

Worth knowing

The FDA says it knows of fake compounded semaglutide and tirzepatide, with labels naming pharmacies that don't exist or real pharmacies that didn't make them5. It has had complaints of compounded GLP-1 drugs arriving warm, and it raises concerns about multi-dose vials used more than 28 days after first use, when the risk of contamination rises5. In February 2026, it said companies can't advertise compounded drugs as generics, as the same as approved drugs, or as clinically proven6. It also says retatrutide can't be used in compounding under federal law, and it has warned sellers of GLP-1 drugs labelled 'for research purposes' or 'not for human consumption'5. Tidepath records what you tell it you're taking. It can't check what's in a vial.

Sources

  1. FDA: Human Drug Compounding (content current as of 06/15/2026)
  2. FDA: Compounding and the FDA: Questions and Answers (content current as of 09/16/2025)
  3. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updates 10/02/2024 to 4/1/2026; content current as of 04/01/2026)
  4. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (content current as of 07/26/2024)
  5. FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026)
  6. FDA Statement: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (February 6, 2026)
  7. Federal Register 2026-08552 (May 1, 2026): List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
  8. Federal Register 2026-12937 (June 26, 2026): extension of comment period

More in Topics